Across TCGA pan-cancer cohorts, FANCB mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FANCB data layer compared with 28 for mass-spec protein and 9 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FANCB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FANCB expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.
HNSC and LSCC are the cancer types where FANCB mass-spec protein most reproducibly stratifies survival.